SCHEMBL1999230

SCHEMBL1999230

CCn1nc(C(=O)O)cc(Nc2cncc3ccccc23)c1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
PDE4B Q07343 10/20 0.41
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ADRA1A P35348 1/20 0.40
MALT1 Q9UDY8 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADORA1 P30542 3/20 0.38
ADORA2A P29274 2/20 0.38
ADORA2B P29275 2/20 0.38
KDM4C Q9H3R0 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997921 0.88 CDC25B (0.44) AURKARPS6KB1PDE4BMAPTL3MBTL1
SCHEMBL2001626 0.86 TRPV1 (0.39) AURKARPS6KB1PDE4BMAPTL3MBTL1
SCHEMBL1994571 0.86 ADORA3 (0.40) AURKARPS6KB1PDE4BMAPTL3MBTL1
SCHEMBL1997594 0.85 GABRA1 (0.40) AURKARPS6KB1PDE4BMAPTL3MBTL1
SCHEMBL1995464 0.85 KMT2A (0.46) MAPTL3MBTL1KDM4EALDH1A1SMN1; SMN2
SCHEMBL1999854 0.84 NPC1 (0.39) AURKARPS6KB1PDE4BMAPTALDH1A1
SCHEMBL4050296 0.83 PDE4B (0.48) PDE4BADORA1ADORA2AADORA2B
SCHEMBL2001982 0.83 POLR1A (0.40) AURKARPS6KB1PDE4BMAPTL3MBTL1
SCHEMBL2001500 0.83 ALDH1A1 (0.39) MAPTKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1998635 0.82 ALDH1A1 (0.41) AURKARPS6KB1PDE4BMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed
EP-1758869-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2007-03-07 EP disclosed
WO-2005123692-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B AURKA 2019/4885RPS6KB1 3437/4885PDE4B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.